Communiqués Neurogene Inc.

Actions

NGNE

US64135M1053

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
44,34 ^USD	-3,08 %		+14,99 %	+128,79 %

18/06	Neurogene administre la dose élevée de NGN-401 à la première patiente de l'essai sur le syndrome de Rett	MT
18/06	Neurogene Inc. annonce la première patiente de la cohorte à haute dose de l'essai clinique de thérapie génique NGN-401 pour le syndrome de Rett	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Neurogene Announces Addition to Russell 3000 Index	02/07	AQ
Neurogene to Participate in BMO Genetic Medicines Summit	02/07	BU
Neurogene Announces Addition to Russell 3000® Index	01/07	BU
Neurogene : Corporate Presentation June 2024	21/06	PU
Neurogene : IRSF Clinical Safety Poster	18/06	PU
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome	18/06	BU
Neurogene to Participate in Upcoming Conferences	05/06	BU
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program	03/06	BU
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	13/05	AQ
Neurogene: Q1 Earnings Snapshot	10/05	AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	10/05	BU
Neurogene : ASGCT NGN-401 Clinical Safety Poster	07/05	PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	07/05	BU
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22/04	BU
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18/03	BU
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03	BU
Neurogene to Participate in Upcoming Investor Conferences	29/02	BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01	BU
Neurogene Announces Business Update and 2024 Outlook	05/01	BU
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million	20/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Neurogene Inc.

Actions

NGNE

US64135M1053

Communiqués

Filtres